Zomedica Pharmaceuticals Corp Stock Today
| ZOM Stock | USD 0.12 0 3.58% |
Performance0 of 100
| Odds Of DistressLess than 20
|
Zomedica Pharmaceuticals is selling at 0.1243 as of the 12th of December 2024; that is 3.58% increase since the beginning of the trading day. The stock's lowest day price was 0.12. Zomedica Pharmaceuticals has about a 20 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 12th of November 2024 and ending today, the 12th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of July 2016 | Category Healthcare | Classification Health Care |
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan. Zomedica Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on AMEX Exchange. The company has 997.95 M outstanding shares of which 51.14 M shares are at this time shorted by investors with about 17.24 days to cover. More on Zomedica Pharmaceuticals Corp
Moving against Zomedica Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Zomedica Stock Highlights
| CEO | Robert Cohen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Zomedica Pharmaceuticals Corp | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsZomedica Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Zomedica Pharmaceuticals' financial leverage. It provides some insight into what part of Zomedica Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Zomedica Pharmaceuticals Corp (ZOM) is traded on NYSE MKT Exchange in USA. It is located in 100 Phoenix Drive, Ann Arbor, MI, United States, 48108 and employs 144 people. Zomedica Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a total capitalization of 147.6 M. Zomedica Pharmaceuticals runs under Pharmaceuticals sector within Health Care industry. The entity has 997.95 M outstanding shares of which 51.14 M shares are at this time shorted by investors with about 17.24 days to cover.
Zomedica Pharmaceuticals Corp has about 27.4 M in cash with (15.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Zomedica Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationZomedica Pharmaceuticals Corp retains a total of 997.95 Million outstanding shares. Roughly 89.97 (%) of Zomedica Pharmaceuticals outstanding shares are held by general public with 1.7 % owned by insiders and only 8.33 percent by institutional investors. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Zomedica Ownership Details
Zomedica Pharmaceuticals Historical Income Statement
Zomedica Stock Against Markets
Zomedica Pharmaceuticals Corporate Directors
| Thomas Robitaille | Independent Director | Profile | |
| Johnny Powers | Independent Director | Profile | |
| Jane Eagleson | Independent Director | Profile | |
| Angy Guerrant | Director of Portfolio Management | Profile |
Already Invested in Zomedica Pharmaceuticals Corp?
The danger of trading Zomedica Pharmaceuticals Corp is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Zomedica Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Zomedica Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Zomedica Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Zomedica Pharmaceuticals is a strong investment it is important to analyze Zomedica Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zomedica Pharmaceuticals' future performance. For an informed investment choice regarding Zomedica Stock, refer to the following important reports: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.06) | Revenue Per Share 0.027 | Quarterly Revenue Growth 0.018 | Return On Assets (0.09) | Return On Equity (0.24) |
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.